Download PDF
Thromb Haemost 2009; 101(04): 782-785
DOI: 10.1160/TH08-09-0617
Letters to the Editor
Schattauer GmbH

The contribution of anti-Xa and anti-IIa activities to the profibrinolytic activity of low-molecular-weight heparins

Concetta T. Ammollo
1   Department of Biomedical Sciences and Human Oncology, Section of General and Experimental Pathology, University of Bari, Bari, Italy
,
Fabrizio Semeraro
1   Department of Biomedical Sciences and Human Oncology, Section of General and Experimental Pathology, University of Bari, Bari, Italy
,
Nicola Semeraro
1   Department of Biomedical Sciences and Human Oncology, Section of General and Experimental Pathology, University of Bari, Bari, Italy
,
Mario Colucci
1   Department of Biomedical Sciences and Human Oncology, Section of General and Experimental Pathology, University of Bari, Bari, Italy
› Author AffiliationsFinancial support: This work was supported in part by a grant from the University of Bari.
Further Information

Publication History

Received: 24 September 2008

Accepted after major revision: 16 January 2009

Publication Date:
23 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Alban S. From heparins to factor Xa inhibitors and beyond. Eur J Clin Invest 2005; 35 (01) 12-20.
    CrossrefPubMedGoogle Scholar
  • 2 Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol 2000; 20: 2511-2518.
    CrossrefPubMedGoogle Scholar
  • 3 Gerotziafas GT, Petropoulou AD, Verdy E. et al. Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation. J Thromb Haemost 2007; 5: 955-962.
    CrossrefPubMedGoogle Scholar
  • 4 Lisman T, Adelmeijer J, Nieuwenhuis HK. et al. Enhancement of fibrinolytic potential in vitro by anticoagulant drugs targeting activated factor X, but not by those inhibiting thrombin or tissue factor. Blood Coagul Fibrinolysis 2003; 14: 557-562.
    CrossrefPubMedGoogle Scholar
  • 5 Colucci M, Binetti BM, Tripodi A. et al. Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism. Blood 2004; 103: 2157-2161.
    CrossrefPubMedGoogle Scholar
  • 6 Semeraro F, Piro D, Rossiello MR. et al. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots. Thromb Haemost 2007; 98: 1208-1214.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Al Dieri R, Wagenvoord R, van Dedem GW. et al. The inhibition of blood coagulation by heparins of different molecular weight is caused by a common functional motif – the C-domain. J Thromb Haemost 2003; 1: 907-914.
    CrossrefPubMedGoogle Scholar
  • 8 Ghosh S, Ezban M, Persson E. et al. Activity and regulation of factor VIIa analogs with increased potency at the endothelial cell surface. J Thromb Haemost 2007; 5: 336-346.
    CrossrefPubMedGoogle Scholar
  • 9 Nagashima H. Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. II. Effects on fibrinolysis. J Biol Chem 2002; 277: 50445-50449.
    CrossrefPubMedGoogle Scholar
  • 10 Weitz JI. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb Haemost 2006; 96: 274-284.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Schutgens RE, Esseboom EU, Snijder RJ. et al. Low molecular weight heparin (dalteparin) is equally effective as unfractionated heparin in reducing coagulation activity and perfusion abnormalities during the early treatment of pulmonary embolism. J Lab Clin Med 2004; 144: 100-107.
    CrossrefPubMedGoogle Scholar